Strategic collaboration Nostrum Biodiscovery is a Barcelona-based spin-off from premier research institutions and already partnered with a major pharma company (Almirall) to explore AI-driven protein design. Target this track record to pursue tier-1 biotech and pharma partnerships seeking advanced molecular modeling, AI-enabled discovery, and immune-oncology or dermatology programs.

Global expansion With clients in over 13 countries and active expansion in Asia, Latin America, and strengthened presence in the US and Europe, there is momentum for international project-based opportunities and regional service partnerships, reseller agreements, or co-development deals.

AI driven Strong emphasis on AI and machine-learning augmented molecular modeling, data augmentation, and fine-tuning, leveraging PyTorch and scikit-learn. Sell opportunities around AI-enabled hit discovery, de novo design, and generative approaches for protein-modulators and nucleic acid therapeutics.

Niche capabilities Specialization in small molecules design, targeted protein degradation, antibodies, immunologics, and enzyme engineering positions Nostrum for niche programs requiring integrated computational chemistry, biology, and bio-based chemistry workflows—ideal for early-phase discovery partnerships and joint ventures.

Funding signals Moderate revenue and recent funding activity indicate growing capacity for contract research or consortium-style projects. Approach for milestone-based service agreements, sponsored research, and scalable outsourcing of computational modeling and high-performance computing-enabled studies.